Replies to post #192970 on Biotech Values

[mcbio]

The probability of recurrence follows an exponential curve, as one would intuitively expect—i.e. there is no significant spike in the recurrence rate during the third year following treatment.

It would seem common sense to me that the further you go out, the greater the likelihood of cancer recurrence. I.e., much greater odds of cancer recurrence in year 3 than year 1.

p.s. The NRG Oncology cooperative likes ADXS’s preliminary anal-cancer data enough to want to conduct a phase-3 trial if NCI provides funding.

I would assume you still agree with the uncontrolled data caveat.

[DewDiligence]

ADXS, AZN start phase-2 trial of ADXS-HPV + Durvalumab (AZN’s checkpoint inhibitor) in HPV-associated (cervical, H&N) cancers:

http://finance.yahoo.com/news/advaxis-medimmune-commence-enrollment-phase-130500622.html